Drug reference
To reduce the frequency of serious infection in chronic granulomatous disease ▶BY SUBCUTANEOUS INJECTION ▶Adult: 50 micrograms/m2 3 times a week To reduce the frequency of serious infection in severe malignant osteopetrosis ▶BY SUBCUTANEOUS INJECTION ▶Adult: 50 micrograms/m2 3 times a week Immune system and malignant disease
PDF page 1031
Simultaneous administration of foreign proteins including immunological products (such as vaccines)—risk of exaggerated immune response
PDF page 1031
Arrhythmias. cardiac disease. congestive heart failure. ischaemia. seizure disorders (including seizures associated with fever)
PDF page 1031
▶Common or very common Abdominal pain. arthralgia. back pain. chills. depression. diarrhoea. fatigue. fever. headache. nausea. rash. vomiting ▶Frequency not known Atrioventricular block. chest discomfort. confusion. connective tissue disorders. embolism and thrombosis. gait abnormal. gastrointestinal haemorrhage. hallucination. heart failure. hepatic failure . hypertriglyceridaemia. hypoglycaemia. hyponatraemia. hypotension. influenza like illness. myocardial infarction. neutropenia. pancreatitis. parkinsonism. proteinuria. renal failure. respiratory disorders. seizure. syncope. systemic lupus erythematosus (SLE). tachycardia. thrombocytopenia. transient ischaemic attack
PDF page 1031
Effective contraception required during treatment—consult product literature.
PDF page 1031
Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies).
PDF page 1031
Manufacturers advise avoid—no information available.
PDF page 1031
Manufacturer advises caution in severe impairment (increased risk of accumulation).
PDF page 1031
Manufacturer advises caution in severe impairment—risk of accumulation.
PDF page 1031
Monitor before and during treatment: haematological tests (including full blood count, differential white cell count, and platelet count), blood chemistry tests (including renal and liver function tests) and urinalysis.
PDF page 1031
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Immukin (Clinigen Healthcare Ltd) Interferon gamma-1b (recombinant human) 200 microgram per 1 ml Immukin 100micrograms/0.5ml solution for injection vials | 6 vial P £450.00 IMMUNOSTIMULANTS › INTERLEUKINS
PDF pages 1031, 1032
50 micrograms/m2 3 times a week
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1031
50 micrograms/m2 3 times a week
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1031
